Mossasar Kopp.
I. PROVIDING DRUG I. Mossaphate is a broad spectrum of dark red filmed clothing and 8-methoxyfluorophenone antibacterials with antibacterial activity. It belongs to the fourth generation of fluoroponone-type drugs, which have a strong antibacterial effect by inhibiting the expansion of the enzyme II (DNA Rotation enzyme) and the expansion of the enzyme IV to disrupt the reproduction of bacteria’ DNA.
II. Adaptive diseases • Respiratory infections:
• Acute bacterial sinusitis: acute bacterial sinusitis caused by, inter alia, pneumococcus, haemophilus influenzae or catamola, is one of the main accommodations of Mossi sachlor. When a patient suffers from snot plugs, sulphate, headaches, and is diagnosed by a doctor as a result of bacterial infections, it can be treated with moxie salsa hydrochloride, usually for 10 consecutive days.
Acute outbreak of chronic bronchitis: Accurate of chronic bronchitis caused by pneumocococcus, haemophilus influenzae, pneumococcus, meoxysicillin-sensitive golden grapepluccus, etc., has better therapeutic effects for Mossasa hydrochloride. Chronic bronchitis patients suffer from acute stress periods, with increased symptoms such as cough, cough and asthma, and the use of the drug is effective in controlling infections and mitigating symptoms, usually for five consecutive days.
Community Access to Pneumonia: Community Access to Pneumonia is contracted outside the hospital, with common pathogens such as pneumocococcus, catamola, methoxysicillin-sensitive golden pneumococcus, crebercus, pneumonia phyllus. Mosisa hydrochloride has better antibacterial effects on these pathogens, and it usually takes between 7 and 14 days for community access to pneumonia.
Skin and soft tissue infections: non-complex skin and skin tissue infections: non-complex skin and skin tissue infections caused by sepsis streptococcus or methoxiline sensitive peptococcus, e.g., gills, gills, cystitis, scabies, etc., treated with mosaic acid, generally for seven consecutive days.
Complex skin and skin tissue infections: For complex skin and skin tissue infections, such as those caused by the sensitive creberella, pneumocococcus, corticolella or glucose intestines, such as deep swollen swollenness, beeweeditis, etc., the treatment cycle is relatively long and requires 7 to 21 days of continuous use.
• Abdominal infections: Intra-bouric complex infections, such as abdominal abscesses caused by colicus, fragile bacillus, streptocococcus, aerobic membrane, polycarbacteria or digestive streptococcus, may be used as one of the therapeutic drugs, usually for a period of 5 to 14 days.
• Other: Bacteria conjunctivitis caused by bacterial bacterial and special pathogens that are sensitive to Mossisha. In addition, as part of the multi-pharmaceutical treatment programme for leprosy, Mossace also plays a role.
Usage • Specification of the formulation type:
There are a number of clinical types of formulations in the salsa of hydrochlorate, including tablets (0.4 g/spoll), injections (sodium chlorinated salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa salsa sa sa salsa salsa sa sa sa sals sa sals sals sa sals sals sa sals sals sa sa sa sa sa sa sa
Specific use: • The tablets are oral and delivered with warm water; injections are injected through intravenous dripping; eye drops are directed to the eye.
• Adults generally give drugs 0.4g every 24 hours. Treatment for different types of infection varies from 10 days for acute bacterial nasal inflammation; 5 days for acute outbreak of chronic bronchitis; 7 to 14 days for community access to sexual pneumonia; 7 days for non-complex skin and skin tissue infections; 7 to 21 days for complex skin and skin tissue infections; 5 to 14 days for complex intraperitoneal infections; 1 drop per drop per day, 3 times per day, 7 days for continuous use.
IV. Adverse effects:
• Cardiovascular system: There may be adverse reactions such as QT inter-term extension, cutting-edge reversal of room cardiac hyperactivity and room heart disorder. For patients who are themselves at risk of heart disease or cardiac abnormalities, special care is required when using Mossacea hydrochloride, and close attention should be paid to the heart condition during drug use.
• Central nervous system: including convulsions, mesotoxic psychosis, tremors, manic movements, anxiety, dizziness, blurred consciousness, hallucinations, delusions, depression, nightmares, insomnia, epilepsy, etc., in very few cases leading to suicidal thoughts or actions. If the patient undergoes an abnormal change in his or her mental state or nervous system during his or her medication, he or she shall be informed in due course.
• Periphery neurological changes: neurological changes such as sensory disorders, retardation, tactile pain, burns, stings, numbness, weakness or light touch, pain, temperature, locational and vibrancy abnormalities, and multiple neuropathy may also occur. Patients who detect physical or motor abnormalities during the course of their medication should be treated in a timely manner.
• Skeletal musculoskeletal system: adverse effects such as joint pain, myocardial pain, muscle weakness, hypertension, mystic inflammation, fissure of myoskeletal muscular fissures, deterioration of the serious musculosculoskeletal system may affect the body’s muscle and bone system. In particular, elderly patients, patients treated with sugar cortex hormones and patients with kidney, heart or pulmonary transplants are at higher risk of myelitis and fissure.
• Hypersensitivity: can be seen in the form of gill measles, itching and other severe skin reactions (e.g., virulent episothelia, hysteria, erythrocyte), respiratory difficulties, vascular edema (including tongue, throat, throat or face oedema/swollen), cardiac hysteria, low blood pressure, loss of consciousness, gastric blockage (including bronchal convulsions, agitation and acute respiratory distress), allergic pneumonia, allergic shock, etc., which may endanger life, requiring immediate detoxification and emergency treatment.
• Hepatitis: may cause adverse reactions to the liver system, such as hepatitis, yellow blubber, acute liver failure or liver failure. Patients should regularly check for liver function during the use of drugs, and if he/she is found to have abnormal liver function, he/she should be stopped and treated in a timely manner.
• Utility system: there is a risk of acute kidney failure or renal failure. Patients should be careful to observe changes in urine during their use, such as reduced urine and abnormal urine colours, and should inform doctors in a timely manner.
Other: There may also be adverse effects such as fever, vascular inflammation, seropathy, indignant diarrhea, blood sugar disorders, photosensitivity/phototoxicity.
V. NOTES
• Prohibited population: allergies of salsac and other quinone-type drugs are banned; pregnant and lactating women are banned; persons under 18 years of age are banned; patients with a history of muscular disease/diseases associated with the treatment of quinone-type drugs are banned; patients with congenital or proven acquired QT prolonged periods, electrolytic disorders, especially uncorrected cases of low potassium haemorrhage, clinically disturbed patients, clinically significant heart failure, accompanied by a reduction in blood fractions in the left heart chamber, and former patients with symptoms.
• Drug interaction: There may be interaction between Mosisa hydrochloride and polydrugs. For example, co-use with West Shabelle, Penedallon and Mesodaron can increase the risk of cardiac toxicity; co-use with sugar-reducing drugs such as benzosulfonol, chlorsulfonpropyl, which can cause blood sugar fluctuations; and co-use with a combination of vitamins containing iron or zinc, anti-acid drugs containing aluminium sulphate, etc., which can reduce the absorption of the Mossisar. Therefore, prior to the use of Mosisa hydrochloride, doctors should be informed of other drugs being used so that they can assess whether they can be used simultaneously.
• Drugs for specific population groups: for elderly patients, for insufficiently functional livers, and for patients lacking G6PD; for patients with severe myocardia and for patients who are using sugar-depressants; and for patients with central nervous system diseases or epilepsy.
• Light sensitivity: During the use of the drug, exposure to the longer wavelength ultraviolet light should be avoided through the sun of the glass window or the bath lamp, so as to avoid light allergy.
VI. Storage of drugs
• The tablets shall be shaded and kept in seals of less than 25°C; the injections shall be shaded, closed, kept at or above 15°C, not refrigerated or frozen, with a short range allowed from 15°C; the eye drops shall be stored at temperatures of 2 to 25°C and shall be used within 28 days after their opening. In short, Mosisa hydrochloride is a relatively anti-bacterial drug, but in its use it is necessary to follow strictly the doctor ‘ s advice and to take care of its use, adverse effects and care to ensure its safety and effectiveness.
